{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-008839","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.799260+00:00","generated_at":"2026-06-06T14:02:33.710291+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TransCode regains Nasdaq equity compliance; still faces bid price rule non-compliance with May 6 deadline","bullets":["Nasdaq determined TransCode met minimum $2.5M stockholders' equity requirement for continued listing.","Company placed on mandatory panel monitor through January 26, 2025, subject to delisting if non-compliant again.","Separately, TransCode remains non-compliant with minimum $1.00 bid price rule; must cure by May 6, 2024.","Failure to meet bid price rule could lead to additional 180-day compliance period if other listing standards are met."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-008839","json":"https://secwatch.observer/filing/0001104659-24-008839.json","markdown":"https://secwatch.observer/filing/0001104659-24-008839.md","text":"https://secwatch.observer/filing/0001104659-24-008839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465924008839/0001104659-24-008839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465924008839/tm244740d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T14:02:33.710291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}